Pancreatic Cancer Research

ResearcherUniversity of California, Los AngelesNo recent work listed

Howard A. Reber

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5110237954. Sources: OpenAlex.

Their work

Papers
23 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
1
Collaborators
57
Papers, trials and grants by year

2011: 6 papers · 2012: 2 papers · 2013: 4 papers · 2014: 1 paper · 2015: 2 papers · 2016: 3 papers · 2017: 1 paper · 2018: 2 papers · 2019: none · 2020: 1 paper · 2021: 1 paper

Papers 23

  1. Poorly differentiated histologic grade correlates with worse survival in SMAD4 negative pancreatic adenocarcinoma patients. Co-author DOI 10.1002/jso.26279↗
  2. Impact of resection margin status on survival in pancreatic cancer patients after neoadjuvant treatment and pancreatoduodenectomy. Co-author DOI 10.1016/j.surg.2019.12.008↗
  3. Low-Dose Continuous 5-Fluorouracil Combined with Leucovorin, nab-Paclitaxel, Oxaliplatin, and Bevacizumab for Patients with Advanced Pancreatic Cancer: A Retro… First author DOI 10.1007/s11523-018-0572-3↗
  4. A Comprehensive Assessment of Accurate Lymph Node Staging and Preoperative Detection in Resected Pancreatic Cancer. Co-author DOI 10.1007/s11605-017-3607-7↗
  5. Pancreatic Cancer Arising From the Remnant Pancreas: Is It a Local Recurrence or New Primary Lesion? Co-author DOI 10.1097/mpa.0000000000000897↗
  6. CA19-9 Normalization During Pre-operative Treatment Predicts Longer Survival for Patients with Locally Progressed Pancreatic Cancer. Co-author DOI 10.1007/s11605-016-3149-4↗
  7. Long-term survival in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.surg.2015.12.024↗
  8. Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer. Co-author DOI 10.1038/bjc.2016.121↗
  9. Pancreatic cancer patients with lymph node involvement by direct tumor extension have similar survival to those with node-negative disease. Co-author DOI 10.1002/jso.24011↗
  10. Surgical management of pancreatic cancer--pancreaticoduodenectomy. First author DOI 10.1053/j.seminoncol.2014.12.009↗
  11. Locally advanced pancreatic cancer: association between prolonged preoperative treatment and lymph-node negativity and overall survival. Co-author DOI 10.1001/jamasurg.2013.2690↗
  12. Simultaneous knock-down of Bcl-xL and Mcl-1 induces apoptosis through Bax activation in pancreatic cancer cells. Co-author DOI 10.1016/j.bbamcr.2013.08.006↗
  13. miR-143 decreases COX-2 mRNA stability and expression in pancreatic cancer cells. Co-author DOI 10.1016/j.bbrc.2013.08.042↗
  14. The flavonoid quercetin inhibits pancreatic cancer growth in vitro and in vivo. Co-author DOI 10.1097/mpa.0b013e318264ccae↗
  15. Impact of tumor grade on pancreatic cancer prognosis: validation of a novel TNMG staging system. Co-author DOI 10.1245/s10434-013-3159-3↗
  16. Evidence for activation of mutated p53 by apigenin in human pancreatic cancer. Co-author DOI 10.1016/j.bbamcr.2011.12.008↗
  17. Apigenin inhibits NNK-induced focal adhesion kinase activation in pancreatic cancer cells. Co-author DOI 10.1097/mpa.0b013e31824d64d9↗
  18. Overexpression of CXCL5 is associated with poor survival in patients with pancreatic cancer. Co-author DOI 10.1016/j.ajpath.2010.11.058↗
  19. Baicalein, a component of Scutellaria baicalensis, induces apoptosis by Mcl-1 down-regulation in human pancreatic cancer cells. Co-author DOI 10.1016/j.bbamcr.2011.05.003↗
  20. N-myc downstream regulated gene-1 expression correlates with reduced pancreatic cancer growth and increased apoptosis in vitro and in vivo. Co-author DOI 10.1016/j.surg.2010.11.002↗
  21. Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. Co-author DOI 10.1016/j.surg.2011.07.006↗
  22. Operative blood loss and survival in pancreatic cancer. First author DOI 10.1097/mpa.0b013e3181fa4706↗
  23. Cyclooxygenase-2 confers growth advantage to syngeneic pancreatic cancer cells. Co-author DOI 10.1097/mpa.0b013e31820b9733↗

Closest collaborators

The 25 strongest of 57 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Oscar Joe Hines · 19 shared papers, 2011–2021 · strength 0.88
  2. Timothy R. Donahue · 12 shared papers, 2011–2021 · strength 0.83
  3. Guido Eibl · 11 shared papers, 2011–2016 · strength 0.36
  4. David W. Dawson · 7 shared papers, 2011–2021 · strength 0.35
  5. Mark D. Girgis · 4 shared papers, 2016–2021 · strength 0.34
  6. Zev A. Wainberg · 5 shared papers, 2013–2021 · strength 0.32
  7. Jonathan C. King · 6 shared papers, 2011–2021 · strength 0.27
  8. Toshiro Masuda · 3 shared papers, 2017–2020 · strength 0.24
  9. V. Raman Muthusamy · 4 shared papers, 2015–2018 · strength 0.23
  10. Matthew M. Rochefort · 5 shared papers, 2013–2016 · strength 0.22
  11. James S. Tomlinson · 5 shared papers, 2013–2016 · strength 0.22
  12. William H. Isacoff · 3 shared papers, 2013–2018 · strength 0.16
  13. Hiroki Takahashi · 5 shared papers, 2011–2013 · strength 0.15
  14. Hideo Baba · 2 shared papers, 2017–2018 · strength 0.15
  15. Brian E. Kadera · 3 shared papers, 2013–2016 · strength 0.14
  16. Michael A. Mederos · 1 shared paper, 2021 · strength 0.13
  17. Joon Y. Park · 1 shared paper, 2021 · strength 0.13
  18. Hanlin L. Wang · 1 shared paper, 2021 · strength 0.13
  19. Hung Pham · 4 shared papers, 2011–2013 · strength 0.13
  20. Andrew Hieu Nguyen · 2 shared papers, 2015–2016 · strength 0.11
  21. Jennifer L. Williams · 2 shared papers, 2015–2016 · strength 0.11
  22. Graham W. Donald · 3 shared papers, 2013–2014 · strength 0.11
  23. Vay Liang W. Go · 4 shared papers, 2011–2013 · strength 0.11
  24. Tatsuo Hata · 1 shared paper, 2020 · strength 0.09
  25. Shimpei Maeda · 1 shared paper, 2020 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.